Fulgent Genetics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ming Hsieh
- Full Time Employees
- 1,313
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 4978 Santa Anita Avenue El Monte CA United States of America 91780
- IPO Date
- Sep 29, 2016
- CIK
- 0001674930
- Website
- fulgentgenetics.com
- Similar Companies
- Business
- Fulgent Genetics, Inc. (FLGT) provides clinical diagnostic and therapeutic development solutions to physicians, patients, hospitals, medical institutions, governmental bodies, payors, and other laboratories in the United States and internationally; its core laboratory services business offers molecular diagnostic testing, genetic testing including next-generation sequencing (NGS) for germline exome/genome analysis, anatomic pathology laboratory tests and services encompassing gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, hematopathology, and immunohistochemistry; oncology tests and services such as liquid biopsy, Fulgent Oncology, and HelioLiver; reproductive health testing; rare disease and infectious disease diagnostics; biopharma services including RNA sequencing, single cell sequencing, and spatial phenotyping; and sequencer services for hereditary cancer and other conditions, all supported by its proprietary Picture Genetics platform featuring gene probes, data suppression algorithms, adaptive learning software, and laboratory information management systems. The company's therapeutic development segment focuses on oncology drug candidates utilizing a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profiles of new and existing cancer drugs, with lead candidate FID-007 advancing in Phase II trials for recurrent/metastatic head and neck squamous cell carcinoma showing promising objective response rates of 51% overall and median progression-free survival of 7.8 months as of preliminary data in 2025, alongside pipeline assets like FID-022 and candidates for non-small cell lung, pancreatic, breast, ovarian, and colon cancers targeting the STING pathway. Founded in 2011 and headquartered in El Monte, California, Fulgent Genetics operates CLIA-certified and CAP-accredited laboratories across multiple U.S. locations including Texas, Arizona, Massachusetts, and New York, with recent achievements encompassing CE certification under the EU In Vitro Diagnostic Regulation for its FulgentExome and Pipeline Manager germline NGS system enabling European expansion, $99 million in funding secured in 2024 to advance diagnostics and therapeutics in oncology and biopharma services, core revenue growth of 17% year-over-year to $84.1 million in Q3 2025 with raised full-year guidance to $325 million, and ongoing strategic presentations at major investor conferences such as UBS Global Healthcare and Piper Sandler in late 2025.
Fulgent Presents Updated FID-007 Data at ASCO 2026
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Reports First Quarter 2026 Financial Results
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
Fulgent Genetics, Inc. (NASDAQ:FLGT) Sees Large Increase in Short Interest
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx